Pancreatic Cancer Research

Clinical trialPhase 2Completed

BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial

Outcome
Results posted; single-arm, no comparison
Phase
Phase 2
Status
Completed
Study type
Interventional
Start
August 2014
Ended
16 March 2022
Enrollment
50 participants
Sites
2
Primary outcomes
Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone.
Sponsor type
Academic / other
Results posted
13 August 2021
Last update
1 August 2022

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 1 August 2022
Primary outcome
Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone.Progression- free survival: FOLFOXA: 5 (3 to 7), n = 48Overall survival: FOLFOXA: 11 (8 to 14), n = 48Values: median months, 95% Confidence IntervalTime frame: Every 3 months for up to 5 yearsNo analysis posted for this outcome (outcome 1)
Participants
FOLFOXA: 50 started, 48 completed
Serious adverse events
FOLFOXA: 10 of 48Participants with at least one serious adverse event, of those at risk, as posted
1 secondary outcome
Response of Patients With Metastatic Pancreatic Cancer Who Receive the FOLFOX-A Regimen
Complete response: FOLFOXA 2/48 [Participants] (first of 4 rows)

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

A standard treatment for your cancer is called FOLFIRINOX (this utilizes the FDA approved chemotherapy drugs fluorouracil, leucovorin, oxaliplatin and irinotecan). In this study you will receive the chemotherapy treatment FOLFOX-A (fluorouracil, oxaliplatin, leucovorin and Abraxane ®) which substitutes irinotecan for the FDA approved chemotherapy drug Abraxane ®. Even though Abraxane is FDA approved for pancreatic cancer, the combination of Abraxane with the other 3 drugs is being investigated. Your doctors are studying the activity and side effects of FOLFOX-A in advanced (metastatic) pancreatic cancer.

Detailed description public domain (ClinicalTrials.gov)

See summary above

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone. [Every 3 months for up to 5 years]. Median, months (95% Confidence Interval). Progression- free survival: FOLFOXA (n=48): 5 (3 to 7). Overall survival: FOLFOXA (n=48): 11 (8 to 14).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Response of Patients With Metastatic Pancreatic Cancer Who Receive the FOLFOX-A Regimen [Every 3 months for up to 5 years.]. Count Of Participants, Participants. Complete response: FOLFOXA (n=48): 2. Partial response: FOLFOXA (n=48): 12. Stable disease: FOLFOXA (n=48): 12. Progressive disease: FOLFOXA (n=48): 22.